Setterwalls advises InDex Pharmaceuticals Holding AB (publ), listed on Nasdaq First North Growth Market, in connection with a rights issue of approximately SEK 533 million. Barclays Bank Ireland PLC and Carnegie Investment Bank AB (publ) acts as Joint Global Coordinators and Joint Bookrunners in connection with the rights issue.
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The Company’s lead asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases.